15/10/02说明:此前论坛服务器频繁出错,现已更换服务器。今后论坛继续数据库备份,不备份上传附件。

肝胆相照论坛

 

 

肝胆相照论坛 论坛 学术讨论& HBV English [肝胆速递] 围产期抗乙肝病毒治疗对孕妇防止肝功能衰 ...
查看: 537|回复: 0
go

[肝胆速递] 围产期抗乙肝病毒治疗对孕妇防止肝功能衰 [复制链接]

Rank: 10Rank: 10Rank: 10

现金
6559 元 
精华
帖子
967 
注册时间
2006-10-2 
最后登录
2023-7-2 

版主勋章 才高八斗

1
发表于 2011-5-25 04:07 |只看该作者 |倒序浏览 |打印
本帖最后由 风雨不动 于 2012-4-14 15:16 编辑

围产期抗乙肝病毒治疗对孕妇防止肝功能衰竭的评估
Efficacy of peripartum antiviral treatment for hepatic failure due to hepatitis B virus

[肝胆速递] :核苷药物可抑制乙肝复制,降低产妇死亡率并降少母婴传播概率。

http://www.ijgo.org/article/PIIS0020729211001688/abstract?rss=yes

Abstract
Objective
To investigate the efficacy of oral nucleosides in preventing hepatic failure during pregnancy (HFP) caused by hepatitis B virus (HBV) infection.

Methods
Besides receiving standard treatment, 70 women with HFP caused by HBV infection joined a study group (n=40) or a control group (n=30) according to their preference. In the study group, 14 women were given lamivudine in the third trimester and an antiviral treatment was continued postpartum. The 26 remaining patients were treated postpartum only, with lamivudine (n=16) or entecavir (n=10).

Results
In the study group, the values for serum HBV DNA and hepatitis B envelope antigen were markedly lower at 1 and 2months than they were at baseline (P<0.001 and P<0.001, respectively). Moreover, the HBV DNA values at 1 and 2months were significantly lower in the study than in the control group (P<0.05). Overall mortality and incidence of intrauterine infection were also significantly lower in the study group (P<0.05). No newborns had any apparent abnormalities in either group.

Conclusion
Treatment with nucleosides suppressed the replication of HBV DNA and led to biochemical improvement. It also reduced maternal mortality and safely decreased mother-to-child HBV transmission.













(6.合.彩).足球.篮球...各类投注开户下注

第一投注.现金网:招代理年薪10万以上:6668.cc
‹ 上一主题|下一主题
你需要登录后才可以回帖 登录 | 注册

肝胆相照论坛

GMT+8, 2024-5-17 07:20 , Processed in 0.013639 second(s), 11 queries , Gzip On.

Powered by Discuz! X1.5

© 2001-2010 Comsenz Inc.